The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees
Open accessAbstract
Background & Aims Direct-acting anti-viral agents suppress hepatitis B virus (HBV) load but must be given lifelong. Stimulation of the innate immune system could increase its ability to control the virus and have long lasting effects, after a finite regimen. We investigated the effects of immune activation with GS-9620—a potent and selective orally active small molecule agonist of Toll-Like Receptor (TLR)7—in chimpanzees with chronic HBV infection. Methods GS-9620 was administered to chimpanzees every other day (3 times each week) for 4 weeks at 1 mg/kg and, after a 1 week rest, for 4 weeks at 2 mg/kg. We measured viral load in plasma and liver samples, the pharmacokinetics of GS-9620, and the following pharmacodynamics parameters: interferon (IFN)-stimulated gene expression, cytokine and chemokine levels, lymphocyte and natural killer cell activation, and viral antigen expression. Clinical pathology parameters were monitored to determine the safety and tolerability of GS-9620. Results Short-term oral administration of GS-9620 provided long-term suppression of serum and liver HBV DNA. The mean maximum reduction of viral DNA was 2.2 logs, which occurred within 1 week of the end of GS-9620 administration; reductions of greater than 1 log persisted for months. Serum levels of HB surface antigen and HB e antigen, and numbers of HBV antigen-positive hepatocytes, were reduced as hepatocyte apoptosis increased. GS-9620 administration induced production of IFN-α and other cytokines and chemokines, and activated ISGs, natural killer cells, and lymphocyte subsets. Conclusions The small molecule GS-9620 activates TLR-7 signaling in immune cells of chimpanzees to induce clearance of HBV-infected cells. This reagent might be developed for treatment of patients with chronic HBV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Plasmacytoid dendritic cells in immunity
Colonna, M., Trinchieri, G., & Liu, Y.-J. (2004) · Nature Immunology · doi:10.1038/ni1141 · Cited by 1,678
Immunology of hepatitis B virus and hepatitis C virus infection
Rehermann, B., & Nascimbeni, M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1573 · Cited by 1,627
Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection
Guidotti, L. G., Rochford, R., Chung, J., Shapiro, M., Purcell, R., & Chisari, F. V. (1999) · Science · doi:10.1126/science.284.5415.825 · Cited by 1,223
Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K. A., Purcell, R. H., & Chisari, F. V. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.68-76.2003 · Cited by 979
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
Nucleic acid recognition by the innate immune system
Barbalat, R., Ewald, S. E., Mouchess, M. L., & Barton, G. M. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101340 · Cited by 577
Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B
Heathcote, E. J., Marcellin, P., Buti, M., Gane, E., De Man, R. A., Krastev, Z., Germanidis, G., Lee, S. S., Flisiak, R., Kaita, K., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.011 · Cited by 462
Tenofovir Disoproxil Fumarate: Clinical Pharmacology and Pharmacokinetics
Kearney, B. P., Flaherty, J. F., & Shah, J. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443090-00003 · Cited by 456
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy
Nguyen, M. H., Wong, G., Gane, E., Kao, J.-H., & Dusheiko, G. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-19 · Cited by 554
Hepatitis B cure: From discovery to regulatory approval
Lok, A. S., Zoulim, F., Dusheiko, G., & Ghany, M. G. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.008 · Cited by 344
The Critical Role of Nonhuman Primates in Medical Research - White Paper
Friedman, H., Haigwood, N., Ator, N., Newsome, W., Allan, J. S., Golos, T. G., Kordower, J. H., Shade, R. E., Goldberg, M. E., Bailey, M. R., et al. (2017) · Pathogens and Immunity · doi:10.20411/pai.v2i3.186 · Cited by 108
Metadata
- Authors
- Lanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., Halcomb, R. L., & Tumas, D. B.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 144
- Issue
- 7
- Pages
- 1508-1517.e10
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2027555120
- Cited by
- 377
- References
- 28
- FWCI
- 26.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. https://app.cochat.ai/papers/10.1053/j.gastro.2013.02.003
- The paper
- Lanford, R. E., Guerra, B., Chavez, D., Giavedoni, L., Hodara, V. L., Brasky, K. M., Fosdick, A., Frey, C. R., Zheng, J., Wolfgang, G., Halcomb, R. L., & Tumas, D. B. (2013). GS-9620, an Oral Agonist of Toll-Like Receptor-7, Induces Prolonged Suppression of Hepatitis B Virus in Chronically Infected Chimpanzees. Gastroenterology. https://doi.org/10.1053/j.gastro.2013.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.